Vasoplegia Clinical Trial
Official title:
Effect of Endotoxinemia on the Incidence of Postoperative Vasoplegia or Vasoplegic Shock Following Cardiothoracic Surgery Using Cardiopulmonary Bypass
This observational study investigates the effect of endotoxinemia on the postoperative incidence of vasoplegia or vasoplegic shock in patients undergoing cardiac surgery with the use of cardiopulmonary bypass.
Through previous research, it has been well established that cardiothoracic surgery using cardiopulmonary bypass (CPB) causes a systemic inflammatory response. This is in part due to the surgical trauma, the extracorporeal circulation and factors that come with it (e.g. blood contact with foreign surfaces, mechanical stress etc.), and ischemia. This inflammatory response is a key contributor to the incidence of vasoplegia and vasoplegic shock following these types of surgery - a common complication that in turn causes significant morbidity and mortality. Over the years, many factors that contribute to this reaction have been discussed. One potential explanation is the release of endotoxin into the bloodstream during CPB. Endotoxin is a molecule that is a part of bacteria which are native to the human gut. In healthy subjects, cell-barriers prevent release of relevant amounts of endotoxin into the blood stream. During major interventions, and especially during cardiac surgery with CPB, this barrier function is impeded, allowing endotoxin levels to rise and potentially exert detrimental effects. While previous studies have indicated that endotoxin may in fact be released into the bloodstream in significant concentrations, and there are some mechanistic explanations to how endotoxin may contribute to the resulting inflammation and vasoplegia, available studies have been small and the evidence is inconclusive. This study aims to show whether different blood-levels of endotoxin are associated with vasoplegia and vasoplegic shock in patients undergoing cardiac surgery with CPB. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05922982 -
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery
|
N/A | |
| Recruiting |
NCT04812717 -
Prevention of Low Blood Pressure After Cardiac Surgery in Heart Failure Patients With a Filter Called CytoSorb.
|
N/A | |
| Withdrawn |
NCT03446599 -
Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery
|
Phase 2 | |
| Recruiting |
NCT02965339 -
Evaluation of the Association Between Pre-existing Endothelial Dysfunction and the Onset of Vasoplegia During Cardiac Surgery With Cardiopulmonary Bypass
|
||
| Recruiting |
NCT05058612 -
Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)
|
Phase 4 | |
| Not yet recruiting |
NCT04301479 -
Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)
|
Phase 3 | |
| Recruiting |
NCT03968926 -
Hypotension During Extracorporeal Circulatory Support Indicated for Cardiogenic Shock
|
||
| Recruiting |
NCT04901169 -
Angiotensin II in Liver Transplantation
|
Phase 2/Phase 3 | |
| Completed |
NCT03744702 -
Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery
|
Early Phase 1 | |
| Not yet recruiting |
NCT02825056 -
Postoperative Hemodynamics Comparison After High Spinal Block With or Without Intrathecal Morphine.
|
Early Phase 1 | |
| Recruiting |
NCT04964492 -
Assessment of the Hemodynamic Effect of Hydroxocabalamin in Refractory Vasodilatory Shock
|
||
| Completed |
NCT03120637 -
Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue
|
Phase 4 | |
| Completed |
NCT05199493 -
Reducing Acute Kidney Injury Occurence by Administering Angiotensin II
|
Phase 3 | |
| Completed |
NCT05354193 -
Analysis of miRNAs Expression in Vasoplegic Syndrome After On-pump Coronary Artery Bypass Surgery
|
||
| Recruiting |
NCT05833828 -
Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery
|